20 results
8-K
EX-10.1
SLRN
Acelyrin Inc
9 May 24
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
8:13am
investigation or proceeding that may be conducted by any Government Agency, including providing documents or other information, without notice to the Company … or contemplated defense, prosecution, or investigation of any claims or demands by or against third parties, or other matters arising from events, acts
8-K
EX-10.2
SLRN
Acelyrin Inc
9 May 24
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
8:13am
understands this Agreement does not limit Employee’s ability to communicate with any Government Agencies or otherwise participate in any investigation … defense, prosecution, or investigation of any claims or demands by or against third parties, or other matters arising from events, acts, or failures
10-K
2023 FY
SLRN
Acelyrin Inc
28 Mar 24
Annual report
4:21pm
liability, including investigation by federal and state authorities. Prescription drug promotional materials must be submitted to the FDA in conjunction … standard of care will be limited. Adverse events and SAEs that emerge during clinical investigation of or treatment with izokibep, lonigutamab, any of our
8-K
EX-99.3
SLRN
Acelyrin Inc
11 Mar 24
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
8:05am
statements. Izokibep is currently under clinical investigation, and no representation is made as of the safety or efficacy of our product candidates … is cautioned not to place undue reliance on these forward-looking statements. Izokibep is currently under clinical investigation, and no representation is made
8-K
EX-10.1
q25kef86zzo953brr06
2 Aug 23
Departure of Directors or Certain Officers
5:05pm
10-Q
xoftsl pbwaio
15 Jun 23
Quarterly report
4:19pm
8-K
EX-3.2
75xphvby oy9
9 May 23
ACELYRIN, INC. Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
4:16pm
424B4
u3ih1we8ef8l6lm
5 May 23
Prospectus supplement with pricing info
4:22pm
S-1/A
EX-10.10
gel76gaoa9ak6awnq
1 May 23
IPO registration (amended)
6:10am
S-1/A
EX-3.4
wcz750idladkncj74
1 May 23
IPO registration (amended)
6:10am
S-1/A
EX-1.1
jmvzis5ov
1 May 23
IPO registration (amended)
6:10am
S-1/A
fzpp 0fzq95
1 May 23
IPO registration (amended)
6:10am
S-1
d7kc zw7xdrk5pr0
13 Apr 23
IPO registration
5:10pm
S-1
EX-10.12
7qhm dvprhz
13 Apr 23
IPO registration
5:10pm
S-1
EX-10.13
zmrcdtld5w9lh08
13 Apr 23
IPO registration
5:10pm
S-1
EX-2.1
l93 wh89hars9jo2mq0
13 Apr 23
IPO registration
5:10pm
- Prev
- 1
- Next